Revenio will publish its Interim Report Q1 2026 on Tuesday, April 28, 2026, approximately at 09.00 a.m. (EEST). An audiocast and teleconference call for analysts and investors will be held in English at 3.00 p.m. (EEST) on the same day. To ask questions, please join the teleconference.

Interim Report Q1 2026

Information page

Press conference

Revenio presented the transaction in English to the media, investors, and analysts in a press conference on April 13, 2026 at 14:00 EET. Watch the recording below.

Revenio accelerates growth and value creation by acquiring Visionix


## Welcome to Revenio's investor website

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.



Key figures

<p>Revenio is a global leader in ophthalmological devices and software solutions. We focus on eye care solutions; our objective is to improve the quality of clinical diagnostics with targeted product innovations and software solutions. </p><a href='/investors/as_an_investment' class='Button'><button class='Button__Element' href=''/investors/as_an_investment'>Read more</button></a>

Revenio as an investment

<p>Our updated growth strategy keeps focusing on the eye care market, aiming to improve clinical diagnostics' quality through specific product innovations.  </p><a href='/investors/as_an_investment/strategy' class='Button'><button class='Button__Element' href=''/investors/as_an_investment/strategy'>Read more</button></a>

Strategy

<p>Our corporate responsibility priorities are based on our strategic guidelines and the value we create for stakeholders, society, the environment, and the climate. </p><a href='/sustainability/sustainability_themes' class='Button'><button class='Button__Element' href='''/sustainability/sustainability_themes'>Read more</button></a>

Sustainability

<p> Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. </p><a href='/about_us/products' class='Button'><button class='Button__Element' href='''/about_us/products'>Read more</button></a>

Products

![](https://storage.googleapis.com/ir-pages-assets-fi/Revenio/elise-zimmerman-ndpRohZL6bE-unsplash.jpg)

### Outlook and guidance

See our guidance

<h2 style="color:white" color:"white">Popular links</h2>

![](https://inderes-ir-pages-prod-assets.storage.googleapis.com/reveniogroup/images/Robin%20Pulkkinen%20Cropped-optimized.jpg)

### Investor contacts

CFO Robin Pulkkinen robin.pulkkinen(at)revenio.fi

Thank you for your answers. We will do our best to develop our operations on the basis of this feedback.

Interim Report Q1 2026

Revenio accelerates growth and value creation by acquiring Visionix

Welcome to Revenio's investor website

Key figures

{{stockPrice}} EUR

{{stockPricePercentageChange}}

{{stockPriceLatestDate}}

109.7

MEUR

2025

23.2

%

2025

Revenio as an investment

Revenio as an investment

Outlook and guidance

Upcoming events

Releases

Latest video

Popular links

Investor contacts